According to a new report by MarketsandMarkets™ – Optometry Equipment Market in terms of revenue was estimated to be worth $4.5 billion in 2024 and is poised to reach $6.1 billion by 2029, growing at a CAGR of 6.4% from 2024 to 2029.
The principal drivers propelling the expansion of this market are the growing prevalence of eye illnesses, advancements in ophthalmic device technology, expanding government initiatives aimed at preventing visual impairment, growing healthcare expenses, and rising disposable incomes. Companies in the market for optometry equipment are finding that developing nations like China, Japan, and India provide attractive opportunities.
According to product type, the worldwide optometry equipment market is divided into three segments: goods for general examinations, cornea and cataract examinations, and products for glaucoma and retinal examinations. In2023, the optometry equipment market was dominated by the sector that produced examination goods for glaucoma and retina. The significant portion of the market is due to a variety of factors, including the expansion of clinics, the increasing incidence of glaucoma and retinal disorders, the easier availability to modern ophthalmic diagnostic technologies, and technological advancements in optometry equipment.
The market for optometry equipment is divided into segments based on applications, including age-related macular degeneration, cataract surgery, glaucoma, and general exams. As of 2023, the worldwide optometry equipment market was dominated by the general examination segment. The primary factors influencing this segment’s size include the aging population, the rise in the prevalence of eye diseases, and the number of cases of diabetes and hypertension.
By end user, the optometry equipment market is divided into eye clinics, hospitals, and other consumers. The sector that held the biggest share of the global optometry equipment market in 2023 was clinics. This sector makes up a sizeable share of the market because of the vast number of patients treated in clinics and the increasing number of private clinical practices founded by ophthalmologists in emerging countries.
There are five main regions that make up the global market for optometry equipment: North America, Europe, Asia Pacific, and Rest of the World (which includes Latin America, the Middle East & Africa, and GCC countries). In terms of market share, North America led the optometry equipment market in 2023. Some of the contributing factors are the rising prevalence of ocular diseases, the rapidly aging population, the accessibility of state-of-the-art optometry equipment, and the growing utilization of ophthalmology procedures and therapies in this field.
Rising government initiatives to control visual impairment
Increasing healthcare expenditure
Restraints:
High cost of optometry equipment
Growing adoption of refurbished optometry equipment
Opportunities:
Growth opportunities in emerging markets
Challenge:
Growth opportunities in emerging markets
Key Market Players of Optometry Equipment Industry:
The major players leading in optometry equipment market are Carl Zeiss Meditec AG (Germany), EssilorLuxottica (France), Alcon (Switzerland), Topcon Corporation (Japan), Bausch Health Companies Inc. (Canada), NIDEK Co. Ltd. (Japan), Canon Inc. (Japan), Johnson and Johnson (US), HEINE Optotechnik (Germany), Revenio Group PLC (Finland), Haag-Streit Group (Switzerland) and Heidelberg Engineering (Germany).
Breakdown of supply-side primary interviews, by company type, designation, and region:
By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
By Designation: C-level (27%), Director-level (18%), and Others (55%)
By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
Recent Developments of Optometry Equipment Industry:
In August 2023, Carl Zeiss launched the ZEISS trifocal technology on a glistening-free hydrophobic C-loop platform and a fully preloaded injector for safe and reliable implantation.
In March 2022, Topcon Corporation launched SOLOS, an automatic lens analyzer that enables advanced, accurate, and efficient lens analysis at the touch of a button.
In September 2023, Bauch + Lomb acquired XIIDRA to grow in the prescription dry eyes segment.
In January 2023Bausch + Lomb acquired AcuFocus to expand its cataract surgical portfolio.
Research Insights: https://www.marketsandmarkets.com/ResearchInsight/optometry-eye-exam-equipment-market.asp
Home Healthcare Market in terms of revenue was estimated to be worth $250.0 billion in 2023 and is poised to reach $383.0 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The primary drivers propelling the growth of this market are the aging population, rising healthcare expenditures, and the increased need for home care due to technological advancements in home healthcare.
The home healthcare market is segmented into testing, screening, and monitoring products; therapeutic products; and mobility care products. In 2022, the home healthcare market will be dominated by therapeutic items, primarily because chronic illnesses like diabetes, cancer, and kidney failure are becoming more common.
The home healthcare market on the basis of service is divided into skilled nursing services, rehabilitation therapy services, hospice & palliative care services, unskilled care services, respiratory therapy services, infusion therapy services, and pregnancy care services. Skilled nursing services have the biggest market share for home healthcare in 2022. The industry is expanding due to factors including the aging population.
On the basis of the indication, the home healthcare market has been segregated into cancer, respiratory diseases, movement disorders, cardiovascular diseases & hypertension, pregnancy, wound care, diabetes, hearing disorders, and other indications. By 2022, the home healthcare market’s greatest share belonged to the other indications category. The growing older population and kidney problems are the main factors propelling this market’s expansion.
The global home healthcare market is segmented into four major regions—North America, Europe, the Asia Pacific, and Rest of the World. North America held the biggest market share for home healthcare in 2022. Due to its high disposable income and growing senior population, North America accounts for a sizable portion of the global industry. On the other hand, throughout the course of the forecast period, the Asia Pacific market is anticipated to develop at the highest CAGR. Rising disposable income and government initiatives to promote home healthcare are the main factors driving growth in the Asia Pacific home healthcare industry.
Rapid growth in elderly population and rising incidence of chronic diseases
Rising R&D investments
Need for cost-effective healthcare delivery due to rising costs
Increased preference for personalized care
Restraint:
Changing reimbursement policies
Limited insurance coverage
Patient safety concerns
Opportunities:
Rising focus on telehealth
Untapped developing regions
Growing demand for home-use therapeutic devices
Growing demand for home sleep apnea tests
Rising preference for home hemodialysis treatment
Challenge:
Shortage of home care workers
Lack of supporting infrastructure
Key Market Players of Home Healthcare Industry:
The major players operating in home healthcare market are Fresenius SE & Co. KGaA (Germany), Abbott (US), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), ResMed, Inc. (US), Linde, Plc (Ireland), F.Hoffmann-La Roche, Ltd. (Switzerland), A&D Company, Limited (Japan), Bayada Home Health Care (US), Invacare Corporation (US), Amedisys (US), LHC Group, Inc. (US), Omron Corporation (Japan), Drive Devilbiss Healthcare (UK), Hamilton Medical (Switzerland), Sunrise Medical (Germany), Roma Medical (UK), Caremax Rehabilitation Equipment Co., Ltd. (China), Vitalograph (UK), Advita Pflegedienst Gmbh (Germany), Renafan Gmbh (Germany), ADMR (France), Apex Medical Corp. (Taiwan), Contec Medical Systems Co., Ltd. (China), Löwenstein Medical Technology Gmbh + Co., KG. (Germany), B. Braun Melsungen Ag (Germany), Baxter International, Inc. (US), Allied Healthcare Products, Inc. (US), Medline Industries, Inc. (US), and Advin Health Care (India).
Research Insights: https://www.marketsandmarkets.com/ResearchInsight/home-healthcare-equipment-market.asp
Cartilage Repair Market / Cartilage Regeneration market in terms of revenue was estimated to be worth $1.3 Billion in 2023 and is poised to reach $2.8 Billion by 2028, growing at a CAGR of 17.2% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. Growth in the Cartilage Repair/Cartilage Regeneration market is mainly driven by the Increasing incidence of osteoarthritis, increasing research funding and investments and the Rising number of sports and accident-related orthopaedic injuries expected to grow the market demand Cartilage Repair/Cartilage Regeneration market during the forecast period.
Based on the treatment modality, the cartilage repair/cartilage regeneration market is divided into two categories which are cell-based including chondrocyte transplantation, growth factors, and stem cells and non-cell-based like tissue scaffolds and cell-free composites. In 2022, the cell-based segment had the largest share in the treatment modality segment which is mainly due to advancements in stem cell- therapies used for cartilage repair.
Based on the Application site, the cartilage repair/cartilage regeneration market is categorized into knees, hips, ankles & feet, and other application sites like nose and shoulder. In 2022, The knee segment holds the largest share of the cartilage repair/cartilage regeneration market. The factors responsible for the growth of the segment are the increasing number of knee arthroscopy procedures and the rising incidence of knee osteoarthritis cases globally.
Based on the Application, the global cartilage repair/cartilage regeneration market is broadly segmented into hyaline cartilage and fibrocartilage. The hyaline cartilage segment accounted for the largest share of the cartilage repair and regeneration market in 2022. Hyaline cartilage is expected to grow highest in the upcoming years due to the increasing number of cartilage repair procedures performed worldwide is the major factor driving the growth of this application segment. Technological advancements, product developments and launches, and growing partnerships between key market players and hospitals are also supporting market growth.
Based on the region segmentation, the cartilage repair/cartilage regeneration market is divided into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the largest share and expects to dominate the cartilage repair/cartilage regeneration market. Growth in the North American market is mainly driven by the rising growth opportunities in emerging economies and growing number of contracts and agreements between market players.
Cartilage Repair Market / Cartilage Regeneration market major players covered in the report, such as:
Smith+Nephew (UK)
DePuy Synthes (Johnson & Johnson) (US)
Zimmer Biomet Holdings, Inc. (US)
Stryker Corporation (US)
Vericel Corporation (US)
B. Braun Melsungen AG (US)
Anika Therapeutics (US)
CONMED Corporation (US)
MEDIPOST (South Korea)
RTI Surgical (US)
Arthrex, Inc. (US)
Regrow Biosciences (India)
Geistlich Pharma AG (Switzerland)
AlloSource (US)
Orthocell Ltd, (Australia)
Matricel GmbH (Germany)
CartiHeal, Inc. (Israel)
Regentis Biomaterials (Israel)
Theracell Advanced Biotechnology (Greece)
LifeNet Health (US)
and Among Others
This research report categorizes the cartilage repair/cartilage regeneration market into the following segments and subsegments:
Regional Split
North America
Europe
Asia Pacific
Rest of the World
Treatment Modality Split
Cell-based
Chondrocyte Transplantation
Stem Cells
Growth Factors
Non-cell-based
Tissue Scaffolds
Cell-free Composites
Application Split
Knee
Hip
Ankle and Foot
Other Application Sites
Application Site Split
Hyaline Cartilage
Fibrocartilage
Key Market Stakeholders:
Senior Management
End User
Finance/Procurement Department
R&D Department
Report Objectives:
To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To define, describe, segment, and forecast the cartilage repair/cartilage regeneration market by Product, Application, Medical specialty and Region
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall cartilage repair/cartilage regeneration market
To forecast the size of the cartilage repair/cartilage regeneration market in four main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, and Rest of the world
To profile key players in the cartilage repair/cartilage regeneration market and comprehensively analyze their core competencies and market shares
To track and analyze competitive developments, such as acquisitions; product launches; expansions; collaborations, agreements, & partnerships; and R&D activities of the leading players in the cartilage repair/cartilage regeneration market.
To benchmark players within the cartilage repair/cartilage regeneration market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Glycated Albumin Assay Market in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Government assistance is stimulating the market. Players in the glycated albumin assay market have significant potential in developing nations like India and Japan. Additionally, the aging population in developed and developing nations would favorably impact the market for glycated albumin assay. The prevalence of age-related illnesses like diabetes and pancreatic disorders is anticipated to rise dramatically as the senior population is forecast to grow quickly. Numerous test prescriptions to assess the levels of creatinine, albumin, glucose, ketones, and bilirubin are caused by diagnosing and treating such disorders, which is driving the market’s expansion. Browse through 100 market data tables and 44 figures spread across 180 pages and the in-depth TOC of the glycated albumin assay market.
Based on application, the glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, mainly due to increased focus on type 2 diabetes care and increased funding for diagnostic research.
The significant market share of this sector is mostly due to an increased emphasis on early disease diagnosis. Additionally, hospitals and diabetes care facilities are committed to providing patients with diabetes-specialized care. Their focus on comprehensive diabetes care makes them primary locations for conducting glycated albumin assays, which are important diagnostic tests for monitoring glycemic control.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. In 2022, the glycated albumin assay market’s largest regional market was North America. The government’s support for regional research and increased funding for the creation of preventive care diagnostics can be used to explain North America’s significant market dominance.
Rising investments in healthcare and life sciences research
Challenges:
Changing regulatory landscape
Key Market Players:
The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China).
In 2022, Asahi Kasei Corporation (Japan) led the glycated albumin assay market. The company has maintained a leading position in the market through its strong presence worldwide. The company partners with third parties to offer integrated solutions. The company’s strategy focuses on four factors: affordability, capacity, outcome certainty, and values. The firm implements tailored pricing solutions to ensure maximum patient access. The company also focuses on developing new pricing models for its customers. Additionally, Asahei strategically invests in R&D to strengthen its position in the market. For instance, the company’s R&D expenditure accounted for USD 5.1 billion in 2022. This rise in R&D spending indicates the company’s growing focus on innovation and diversification in emerging markets.
In 2022, Beijing Strong Biotechnologies, Inc. (China) was the second-largest market player in the glycated albumin assay ecosystem. It has an increased presence in Asia Pacific with a strong network and growth strategies and has a product portfolio in the glycated albumin assay market. The company focuses on increasing R&D with increased investment in innovation.
Hymes Biotech, a prominent player in the global glycated albumin assay market, secured a significant market share in the glycated albumin assay market in 2022. The company’s strong presence in China serves as a foundation for expanding its operations in emerging markets like Asia Pacific, thereby strengthening its geographical reach. The company focuses on research and development as well as expanding the manufacturing of the glycated albumin assay market. These strategic initiatives enable Hymes to secure a larger market share and strengthen its position in the glycated albumin assay market.
According to a new report by MarketsandMarkets™ – Mental Health Screening Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.8 billion by 2029, growing at a CAGR of 12.2% from 2023 to 2029.
The growth in the Mental Health Screening market is driven by the growing geriatric population and subsequent increase in the prevalence of mental disorders, rising awareness of mental health issues, technological advancements, and the increasing focus on remote monitoring. The adoption of mental health screening tools is also expected to increase with the integration with wearable technologies and the rise of social media. But the stigma and limited awareness and data privacy concerns may pose a challenge to the Mental Health Screening market during the forecast period.
Based on applications, the mental health screening market is segmented into physiological, psychiatric, behavioral, and cognitive disorders. Physiological disorders are further segmented into depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, eating disorder, substance abuse, and other physiological disorders. Psychiatric disorders are further segmented into schizophrenia, psychotic disorder, dissociative disorder, obsessive compulsive disorder, dissociative disorder, attention deficit hyperactivity disorder (ADHD), and other psychiatric disorders. Behavioral disorders are again segmented into self-harm, aggression, sleep disorder, social withdrawal, dissociative disorder, hyperactivity, and other behavioral disorders. Cognitive disorders are segmented into cognitive impairment, dementia, Alzheimer’s disease, and other cognitive disorders.
The cognitive disorders is the fastest growing in Mental Health Screening market in 2022 attributing to the rising geriatric population, increasing incidence of neurodegenerative diseases, growing awareness, and improved access to screening tools. These disorders can significantly impact an individual’s ability to perform daily activities and maintain independence. It often affects older adults, but it can also occur in younger individuals due to factors like traumatic brain injury, genetic predispositions, or neurological conditions.
Based on screening methods, the global mental health screening market is segmented into self-reported questionnaires & surveys, clinical interviews, observation-based assessments, and biomarker testing. The self-reported questionnaires & surveys segment dominated the mental health screening market in 2022 attributing to the easy availability of a wide variety of questionnaires at affordable prices over digital platforms and availability of self-reported questionnaires & surveys in multilingual formats. Moreover, the ongoing advancements in questionnaire designs are key factors propelling the global adoption of self-reported questionnaire-based assessments in mental health screening.
Based on setting, the Mental Health Screening market is segmented into clinical settings, educational institutions, workplace/corporate programs, online platforms, and other settings. The online platforms segment is expected to register the highest growth rate in the forecast period attributing to the easily accessible and personalized assessments to the patients. Moreover, online platforms use a combination of screening methods to provide users with comprehensive, accessible, and personalized assessments of their mental health status and needs. Thus, promoting mental health awareness, early intervention, and access to support services for individuals seeking assistance with their mental well-being.
The Mental Health Screening market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, North America accounted for the largest share of the Mental Health Screening market. As this region is home to a significant number of mental health screening solution manufacturers. Moreover, the growing number of people requiring mental health services, increasing mental health reforms, and the availability of government funding for expanding mental health services in the region, reinforces its position at the forefront of the mental health screening market.
Growing geriatric population and subsequent increase in prevalence of mental disorders
Rising awareness of mental health issues
Technological advancements
Increasing focus on remote monitoring
Restraints:
Stigma and limited awareness
Data privacy concerns
Opportunities:
Integration with wearable technologies
Rise of social media and its impact on adoption of mental health screening tools
Challenge:
Concerns regarding accuracy and validity
Key Market Players of Mental Health Screening Industry:
Prominent players in the Mental Health Screening market include Adaptive Testing Technologies (US), Proem Behavioral Health (US), Aiberry (US), SonderMind Inc. (US), Clarigent Health (US), Riverside Community Care (US), Kintsugi Mindful Wellness, Inc. (US), Thymia Limited (UK), Ellipsis Health Inc. (US), Canary Speech, Inc. (US), Headspace Health (US), Quartet Health, Inc. (US), Modern Life, Inc. (US), Sonde Health, Inc. (US), FuturesTHRIVE (US), Koninklijke Philips N.V. (Netherlands), Alphabet Inc. (Fitbit) (US), ResMed (US), Apple Inc. (US), MoodFit (US), Wellin5 USA Inc. (Canada), MoodTools (US), Cognitive Health Solutions LLC (US), Woebot Labs Inc. (US), and CogniABle (India).
Medical Display Market in terms of revenue was estimated to be worth $ 2.3 billion in 2023 and is poised to reach $2.9 billion by 2028, growing at a CAGR of 5.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.
The global Medical Display market is like rising technological advancements, increasing demand for diagnostic imaging, rising awareness and adoption of minimally invasive procedures and surge in telemedicine and remote diagnostics. However, market saturation in developed countries and increasing adoption of refurbished medical displays will be challenges in the growth of this market during the forecast period.
In this report, the Medical Display Market is segmented based on technology, panel size, resolution, display color, application and region.
The Medical Display Market is categorized into five segments, including technology, panel size, resolution, display color, application. Among these categories, the color segment in display color is projected to experience the highest growth rate from 2023 to 2028. Enhanced visualization, technological advancements, increasing complexity of medical imaging, improved patient care and safety, integration with picture archiving and communication systems (PACS), and advantages of color displays over grayscale displays such as enhanced contrast and differentiation, improved depth perception, enhanced communication and collaboration, multi-modality application are responsible for the large adoption of color display.
The Medical Display Market is categorized into different technology, including LED-Backlit LCD Displays, CCFL-Backlit LCD Displays, OLED Displays. Among these, the OLED displays segment held the fastest-growing market for medical display market in 2022. This significant market share can be attributed to factors such as fast response time and high refresh rates of OLED displays enable real-time visualization of moving structures, making them valuable for procedures that require precise guidance and monitoring, such as minimally invasive surgeries and endoscopy.
The Medical Display Market is segmented into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, Europe emerged as the second dominant market for Medical Display worldwide. The increasing demand for Medical Display and the availability of advanced technologies are expected to be major driving factors for market growth in Europe. The region’s substantial market share can be attributed to its well-developed healthcare infrastructure and the continuous investment in research and development of medical devices.
Increasing Preference for Minimally Invasive Treatments
Rising Number of Diagnostic Imaging Centers
Restraints:
Market Saturation in Developed Countries
Increasing Adoption of Refurbished Medical Displays
Opportunities:
Development of Healthcare Infrastructure in Emerging Markets
Technological Advancements
Challenges:
Adoption of Consumer-Grade Displays
Fluctuating Average Selling Prices of Display Panels
Key Market Players:
The prominent players in the global Medical Display Market are Barco NV (Belgium), Eizo (Japan), Sony Electronics Inc. (Japan), Lg Electronics (South Korea), Novanta (US), FSN Medical Technologies (South Korea), Advantech (Taiwan), Quest International (US), Steris (UK), Jusha Medical (China), Siemens Healthineers Ag (Germany), Double Black Imaging (US), HP Development Co. Ltd (US), Stryker (US), and Coje Display (South Korea)
Recent Developments:
In April 2023, LG electronics launched 32HQ713D-B, which has latest high-resolution 8MP diagnostic medical monitor. It combines 1000 nits of brightness with LG’s proprietary IPS Black panel to deliver an enhanced 2,000:1 contrast ratio with deep blacks, while greatly simplifying color calibration through an automatic integrated sensor and software.
In February 2023, Eizo launched a 21.3-inch 2-megapixel (1200 x 1600 pixels) color monitor for displaying patient charts and reviewing diagnostic imaging in hospital and clinic environments.
In November 2022, Barco launched two displays. Io Gray 5.8 MP for the breast imaging and MDSC-8532 and MDSC-8527 4K UHD for surgical display.
In July 2022, Eizo launched launched four new monitors ranging from 32 to 55 inches with 4K UHD resolution (3840 x 2160 pixels) for use in endoscopy, microsurgery, and other high-precision procedures in the operating room (OR).
Multiplex Assays Market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach $5.3 billion by 2027, growing at a CAGR of 8.8% from 2022 to 2027 according to a new report by MarketsandMarkets™.
Growth in this market is mainly driven by factors such as the emerging applications of multiplex assay in companion diagnostics and the growing need for automated and efficient systems in laboratories.
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Product & service, type, technology, application, end user, and region
Geographies Covered
North America, Europe, Asia Pacific, and the Rest of the World
Report Highlights
Updated financial information / product portfolio of players
The multiplex assays market is segmented into protein, nucleic acid, and cell-based multiplex assays according to type. The protein multiplex assays segment accounted for the largest share in the global multiplex assays market in 2022. As compared to traditional assays, protein multiplex assays prove to be faster and more efficient for protein profiling. Protein assays are highly efficient, require minimal sample volumes, and help reduce turnaround times; however, the equipment is expensive and requires skilled labor. This is expected to hamper the growth of the protein assays market.
Based on applications, the multiplex assays market is segmented into research & development and clinical diagnostics. The clinical diagnostics segment is further segmented into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism & endocrinology disorders, and other diseases. In 2022, the infectious diseases segment accounted for the largest share of the multiplex assays market for clinical diagnostics. Conventional analytical techniques that are used for the detection and identification of pathogens, such as ELISA and cell culture assays, take 2–3 days to produce results. Some multiplex assays, on the other hand, can provide results in a day or less; their rapidity is the key factor supporting their adoption in infectious disease diagnostics.
The global multiplex assays market has been segmented into five major regions—North America, Europe, the Asia Pacific, and the Rest of the World. In 2022, North America accounted for the largest share of the multiplex assays market. The large share of this region can be attributed to the highly advanced healthcare system in the US and Canada. Over the years, healthcare spending in North America has increased at a significant rate. National health spending is projected to grow at an average annual rate of 5.4% during 2019–2028 and reach USD 6.2 trillion by 2028 (Source: Centers for Medicare & Medicaid Services). The growing healthcare expenditure is also one of the major drivers for the biotechnology sector.
Multiplex Assays Market Dynamics:
Drivers:
Increasing prevalence of chronic respiratory diseases
Growing demand for emergency and intensive care
Growing incidence of pre-term births globally
Government support for improving emergency care infrastructure
Restraints:
Lack of reimbursement policies across developing countries
Opportunities:
Growing demand for single-use Multiplex Assays
Increased growth potential in emerging countries
Challenges:
Harmful effects of Multiplex Assays on neonatal patients
Dearth of skilled professionals for airway management procedures
Increasing pricing pressure on key market players
Key Market Players:
The major players operating in this market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US).
The global Veterinary API Market is estimated to grow significantly. By 2028, it is projected to reach a value of USD 11.9 billion, showing a compound annual growth rate (CAGR) of 6.9% during the forecast period, starting from USD 8.5 billion in 2023 according to a new report by MarketsandMarkets™. The expansion of the Veterinary API Market is driven by various factors, including rising incidence of transboundary & zoonotic diseases, increasing animal population and pet ownership, and increasing disease control & disease prevention measures.
The Veterinary API Market is divided into three types based on synthesis types such as Chemical based API, Biological API, and Highly potent API. The Chemical based API segment accounted for the highest share of the global Veterinary API Market in 2022. Increasing Demand for Plasma-Derived Medicinal Products, Advancements in Plasma Fractionation Technologies, and Growing Need for Cold Chain Infrastructure all some of the factors that are anticipated to promote market expansion throughout the projected period. Growing demand for veterinary medicines, occurrence of new or emerging infectious diseases, and increasing research and development activities are some of the factors that are anticipated to promote market expansion throughout the projected period.
The Veterinary API Market, based on Animal Type is divided into two types such as companion animals and livestock animals. In 2022, companion animals held the highest market share for Veterinary API Market. Growing emphasis on preventive healthcare for companion animals and Increasing pet ownership are some of the factors that contribute to the big proportion of this market.
In the forecast period, Asia Pacific in the Veterinary API Market will have the fastest rising regional growth. Large number of veterinary hospitals and healthcare facilities, increasing spread of diseases in animals, and rising manufacturing infrasturcture for veterinary API manufacturing are the main factors driving market growth. Asia Pacific region has experienced an increase in pet ownership, coupled with a rising awareness of animal health and welfare. This has led to a higher demand for veterinary medicines and APIs in the region. Many countries in the Asia Pacific region, such as China, India, and South Korea, have seen substantial economic growth and increased disposable income. This has resulted in a greater ability and willingness to invest in the healthcare of companion animals, driving the expansion of veterinary API manufacturing infrastructure.
Following is a list of the major players (supply-side) in the Veterinary API Market that this study refers to:
By Company Type: Tier 1- 34%, Tier 2- 46%, and Tier 3- 20%
By Designation: C-level- 35%, Director Level—25%, and Others- 40%
By Region: North America-30%, Europe-45%, Asia Pacific-20%, Latin America- 3%, and Middle East and Africa-2%
Research Coverage:
The market study analyzes the main market segments for Veterinary APIs. The objective of this study is to estimate the market’s size and growth potential across several categories according to API Type, Synthesis Type, Route of Administration, and Animal Type. The report also provides a thorough competition analysis of the major market participants, together with company profiles, major insights regarding their product and service offerings, recent advancements, and key market strategies.
The prominent players in the global Veterinary API Market are
Phibro Animal Health Corporation (US)
Fabbrica Italiana Sintetici S.p.A. (Italy)
Sequent Scientific Ltd. (India)
Excel Industries Ltd. (India)
NGL Fine-Chem Ltd. (India)
Insulnsud Pharma (Spain)
Menadiona Sl (Spain)
Rochem International Inc. (US)
and Shaanxi Hanjiang Pharmaceutical Group Co. Ltd. (China)
Recent Developments:
In 2021, Sequent Scientific Ltd. (India) received WHO–GENEVA approval for API Praziquantel (Anthelmintic) under the prequalification program.
In 2020, Sequent Scientific Ltd. Opened a state-of-the-art animal health R&D center in Mumbai, India.
Adhesion Barrier Market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 7.4%.
The main drivers promoting the development of this market are the rising number of surgeries and sports-related injuries, an increasing elderly population, and the rising awareness of adhesion formation and diseases associated with adhesions.
The prominent players operating in the adhesion barriers market are Baxter International (US), Johnson & Johnson (J&J) (US), and Becton, Dickinson and Company (US), Integra LifeSciences (US), Anika Therapeutics (US), Atrium Medical Corporation (US), FzioMed (US), MAST Biosurgery (Switzerland), Innocoll (Ireland), Betatech Medical (Turkey), CorMatrix Cardiovascular, Inc. (US), Terumo Corporation (Japan), BiosCompass (US), W.L.Gore & Associates (US), GUNZE Limited (Japan), Leader Biomedical (Netherlands), Xlynk Surgical (US), Luna Solutions (US), PlantTec Medical GmbH (Germany), Actamax Surgical Materials, LLC (US), Arc Medical Devices, INC. (US), CG Bio INC. (Korea), Seikagaku Corporation (Japan), Hangzhou Singclean Medical Products Co.,Ltd (China)and Allosource (US).
Based on products, the adhesion barriers market is further segmented into synthetic and natural adhesion barriers. Synthetic adhesion barriers are further classified into hyaluronic acid, regenerated cellulose, polyethylene glycol, and other synthetic adhesion barriers. the hyaluronic acid based adhesion barriers segment accounted for the largest share of the synthetic adhesion barrier market, owing to their properties of biocompatibility and bioresorbable.
In 2022, based on applications, General/Abdominal Surgeries held the largest share of the adhesion barriers market. The large share of this segment can be attributed to factors such as the higher risk of post-surgical adhesion formation in General/Abdominal Surgeries, the growing volume of General/Abdominal Surgeries, and the availability of several commercialized adhesion barrier products for General/Abdominal Surgeries.
On the basis of region, the adhesion barriers market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Adhesion barrier market is expected to grow in the APAC due to factors such as steadily increasing geriatric population, the epidemiological shift from infectious to chronic diseases, and rising medical tourism. As a result, the APAC is anticipated to grow faster than other regions during the forecast period with the highest CAGR.
Recent Developments:
In February 2020, Baxter’s acquired the Seprafilm Adhesion Barrier and related assets from Sanofi to strengthen its hemostate and sealant portfolio and company’s presence in this market.
In January 2021, Integra Lifesciences Holdings Corporation acquired Acell Inc. This acquisition enables integra to provide more comprehensive complex wound management solutions.
Mass Spectrometry Market in terms of revenue was estimated to be worth $5.4 billion in 2023 and is poised to reach $7.8 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™.
The rise in advantages offered by mass spectrometry to be used in therapeutics is one of the major factors anticipated to boost market growth in the forecasting years.
Mass Spectrometry Market by Product (Instrument (Triple Quadrupole, Q-TOF, FTMS, Quadrupole, TOF), Services), Sample Preparation (LC-MS, GC-MS), Application (Omics, Clinical, Environmental), End User (Pharma, Academia, F&B) & Region – Forecasts to 2028
Mass Spectrometry Key Market Players:
The mass spectrometry business is very competitive, with both established companies and newcomers competing for the same market share. As of 2022, the key players operating in the global mass spectrometry market are SCIEX AB (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan) and Bruker Corporation (US) among others.
Based on product, the mass spectrometry market is segmented into instrument and software & services. Instruments are expected to dominate the mass spectrometry market during the forecast period. Due to its excellent high throughput screening, ability of rapid and high-resolution testing, and usage for various applications is highly advantageous.
Based on sample preparation technique, the mass spectrometry is segmented into GC-MS, LC-MS, ICP-MS, and others. LC-MS are expected to dominate the mass spectrometry market during the forecast period. The growth is attributed to its broad applicability to a wide range of rigorous demands of the analytical market and industries.
Based on applications, the mass spectrometry market is segmented into OMICS research, drug discovery, environmental testing, food testing, pharma-biopharma manufacturing, clinical diagnostics, applied industries, and other applications. The OMICS research segment is estimated to hold the largest market share of the mass spectrometry market during the forecast period. The segment includes life science related research like Genomics, Proteomics and Metabolomics.
The end-user market is segmented pharmaceutical companies, biotechnology companies, research labs & academic institutes, environmental testing labs, F&B industry, forensic labs, petrochemical industry and other end users. Pharmaceutical companies accounted for the largest share of the global mass spectrometry market in 2022. This end-user segment is also estimated to grow at the highest CAGR during the forecast period. This can be attributed to the factors such as presence of stringent regulatory guidelines for drug development and safety and availability of government and corporate funding for pharmaceutical research.
The mass spectrometry market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market in the North America region is expected to hold significant market share for mass spectrometry in 2022. The growth of the mass spectrometry market in this region can be attributed to the increasing investments in pharmaceutical R&D and government funding for R&D activities.
Recent Developments:
In January 2022, Thermo Fisher and Symphogen extended their collaborative partnership with aim to deliver workflows for simplified characterization and quality monitoring of complex therapeutic proteins using the Thermo Scientific Q Exactive Plus Orbitrap LC-MS/MS system.
In February 2023, SCIEX announced collaboration with HighRes Biosolutions to bring customizable automation solutions powered by Cellario software, which would add automation benefits to the Echo MS system.
In February 2022, Waters Corporation acquired Charge Detection Mass Spectrometry technology assets and intellectual property rights of Megadalton Solutions, Inc., to broaden its application in Cell and Gene Therapy.
In September 2022, Agilent Technologies partnered with MOBILion Systems for ion mobility separation technology called Structures for Lossless Ion Manipulation (SLIM) on its Q-TOF mass spectrometers.
